Evidence map›Paper›PMID 32631005›Full record

ReviewTurkish journal of ophthalmology2020

Behçet's Uveitis: Current Diagnostic and Therapeutic Approach

Pınar Çakar Özdal

Open access · diamondAbstract readReview
In one paragraph

Review in Turkish journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Association between choroidal vascularity index and disease activity in Behçet uveitis using BOS24 and FFA scores.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Treatment of Behçet Uveitis in Türkiye.Turkish journal of ophthalmology · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Biological therapy for ocular Behçet's disease with off-label drug prescription in Turkey.European journal of hospital pharmacy : science and practice · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Behçet's disease: A review of the ophthalmologic findings reported in Behçet's original descriptions.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
  19. Observational
  20. Clinical Features of Behçet's Disease Uveitis.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Pınar Çakar ÖzdalUniversity of Health Sciences Turkey, Ulucanlar Eye Training and Research Hospital, Clinic of Ophthalmology, Ankara, Turkey.ORCID 0000-0002-5714-7172
Sağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's disease is a chronic, multisystem inflammatory disorder characterized by relapsing inflammation. Although its etiopathogenesis has not yet been clarified, both the adaptive and innate immune systems, genetic predisposition, and environmental factors have all been implicated. It is more frequent and more severe in males in the third and fourth decades of life. The eye is the most frequently involved organ in the course of the disease. Ocular involvement (Behçet's uveitis) is characterized by bilateral recurrent non-granulomatous panuveitis and occlusive retinal vasculitis. Recurrent inflammatory episodes in the posterior segment may lead to permanent vision loss due to irreversible retinal damage and complications such as macular scarring, macular atrophy, and optic atrophy. Early and aggressive immunomodulatory treatment and the use of biologic agents when needed are crucial for preventing recurrences and improving visual prognosis.

Indexed as

Disease ManagementBehcet SyndromeBiological FactorsGlucocorticoidsHumansImmunosuppressive AgentsPrognosisRecurrenceRetinaBiological FactorsGlucocorticoidsImmunosuppressive AgentsBehçet’s uveitisbiologicsimagingprognosistreatment

Identifiers

PMID32631005
PMCPMC7338748
OpenAlexW3038911022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.